Document is current
Any future updates will be listed below
-
Authors
Hedenstierna, Louise
Hedström, Anna Karin
Klareskog, Lars
Di Giuseppe, Daniela
Alfredsson, Lars
Askling, Johan
Ernestam, Sofia
Saevarsdottir, Saedis
Ljung, Lotta
-
Funding
Funding for this research was provided by:
Stiftelsen Börje Dahlins Fond
Vetenskapsrådet
Hjärt-Lungfonden
Stiftelsen Konung Gustaf V:s Jubileumsfond
Stockholms Läns Landsting
Reumatikerförbundet
Forskningsrådet om Hälsa, Arbetsliv och Välfärd
Karolinska Institute
- License Information
-
More Information
Article History
Received: 29 April 2022
Accepted: 5 August 2022
First Online: 23 August 2022
Declarations
:
: The study was approved by the Ethical Review Board at Karolinska Institutet, Stockholm, Sweden (reference numbers 2007/0889-31, 2007/1443-32, 2015/1844-31/2). All participants in the study gave their written informed consent.
: Not required.
: L.L. chairs the steering committee of the Swedish Rheumatology Quality Register, SRQ. Karolinska University Hospital and its principal investigator SRQ have had agreements for register data analyses with Abbvie, Amgen, BMS, Eli Lilly, Galapagos, Janssen, Novartis, Pfizer, Sanofi, Sobi, and UCB. Karolinska Institutet has entered into research agreements with Abbvie, Astra-Zeneca, BMS, Eli Lilly, Galapagos, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi, and UCB, with JA as PI, mainly regarding the safety monitoring of rheumatology immunomodulators. SS is a part-time employee of deCODE genetics Inc., unrelated to this work.
